China Pharma Inc. (CPHI) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    China Pharma Inc.

    AMEX: CPHI · Real-Time Price · USD
    1.91
    -0.04 (-2.05%)
    At close: Sep 26, 2025, 3:59 PM
    1.87
    -1.88%
    After-hours: Sep 26, 2025, 05:30 PM EDT

    China Pharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 4.53M 7.01M 8.1M 9.64M
    Cost of Revenue
    		 6.51M 7.29M 8.6M 9.29M
    Gross Profit
    		 -1.99M -281.08K -493.92K 349.27K
    Operating Income
    		 -4.59M -2.75M -3.55M -3.12M
    Interest Income
    		 6.64K 6.6K 10.76K 3.04K
    Pretax Income
    		 -4.74M -3.08M -3.97M -3.4M
    Net Income
    		 -4.74M -3.08M -10.22M -3.94M
    Selling & General & Admin
    		 2.31M 2.25M 2.96M 3.15M
    Research & Development
    		 283.94K 240.08K 185.86K 318.96K
    Other Expenses
    		 5.7K -15.76K 93.85K n/a
    Operating Expenses
    		 2.6M 2.47M 3.15M 3.46M
    Interest Expense
    		 154.14K 333.6K 434.62K 542K
    Selling & Marketing Expenses
    		 528.82K 780.33K 1.07M 1.5M
    Cost & Expenses
    		 9.12M 9.76M 5.54M 12.76M
    Income Tax Expense
    		 n/a n/a 6.25M 542K
    Shares Outstanding (Basic)
    		 17.46M 10.6M 5.26M 4.61M
    Shares Outstanding (Diluted)
    		 17.46M 10.6M 5.26M 4.61M
    EPS (Basic)
    		 -0.27 -0.29 -1.94 -0.85
    EPS (Diluted)
    		 -0.27 -0.29 -1.94 -0.85
    EBITDA
    		 -1.96M 8.44K -837.69K 230.34K
    EBIT
    		 -4.58M -2.75M -3.54M -2.86M
    Depreciation & Amortization
    		 2.62M 2.75M 2.7M 3.09M

    Add to Watchlist